Savara Inc SVRA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if SVRA is a good fit for your portfolio.
News
-
Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024
-
Savara Announces New Employment Inducement Grant
-
Savara Reports Fourth Quarter/Year-End 2023 Financial Results and Provides Business Update
-
Savara to Present at the Barclays 26th Annual Global Healthcare Conference
-
Savara Announces New Employment Inducement Grant
-
Savara to Present at Two Upcoming Healthcare Conferences
Trading Information
- Previous Close Price
- $4.24
- Day Range
- $4.06–4.46
- 52-Week Range
- $1.78–5.70
- Bid/Ask
- $4.50 / $4.98
- Market Cap
- $614.76 Mil
- Volume/Avg
- 1.3 Mil / 868,443
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 37
- Website
- https://www.savarapharma.com
Comparables
Valuation
|
Metric
|
SVRA
|
ICVX
|
HLVX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 4.38 | 3.30 | 2.26 |
Price/Sales | — | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
SVRA
ICVX
HLVX
Financial Strength
|
Metric
|
SVRA
|
ICVX
|
HLVX
|
|---|---|---|---|
Quick Ratio | 15.41 | 17.59 | 10.37 |
Current Ratio | 15.66 | 18.06 | 10.62 |
Interest Coverage | — | — | −54.72 |
Quick Ratio
SVRA
ICVX
HLVX
Profitability
|
Metric
|
SVRA
|
ICVX
|
HLVX
|
|---|---|---|---|
Return on Assets (Normalized) | −33.79% | −29.30% | −34.03% |
Return on Equity (Normalized) | −43.57% | −31.87% | −42.52% |
Return on Invested Capital (Normalized) | −38.63% | −34.69% | −38.62% |
Return on Assets
SVRA
ICVX
HLVX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Bnnykxmpf | Nkyv | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Qbynrplt | Dwbnqm | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Vjdljywb | Lnsgxq | $97.8 Bil | |
MRNA
| Moderna Inc | Vvhzbty | Qszr | $38.8 Bil | |
ARGX
| argenx SE ADR | Bgxsbdsq | Bvy | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Qhgllcnx | Tzgkn | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Nhdxzwkyc | Rcbckh | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Lpddjvcbv | Vmlrv | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Tbktrdmtl | Dnfsvv | $12.5 Bil | |
INCY
| Incyte Corp | Vkhhzsfhw | Ksccpjh | $11.6 Bil |